Studies which aim at mapping genes contributing to the development of asthma and atopy demand that hundreds of patients and their family members be assessed. In Finland, the Social Insurance Institution (SII) grants substantial reimbursement for medication to all patients who meet diagnostic criteria of asthma, which include a history of asthmatic symptoms and a measured reversibility of bronchial obstruction.
Introduction
The mode of inheritance and the magnitude of a genetic effect compared to environmental factors in the development of asthma and other atopic diseases have been traditionally studied in families and in twins. In these large, often population-based epidemiological studies which include up to thousands of study subjects, the diagnosis of asthma is usually based on patients' self-reporting of the disease (1). Such questionnaire-based studies have been criticized for diagnostic inaccuracy. Lately a more specific question on physician-diagnosed asthma or allergic rhinitis has been used to avoid this problem (2,3). However, at a population level, atopic diseases may still be misdiagnosed and false-negative cases especially may cause uncertainty in the epidemiology of atopic diseases (4). Genetic studies, which aim to identify susceptibility loci for multifactorial diseases such as asthma, also require a large number of study families (5). The expenses incurred in a careful clinical examination which include or exclude asthma in several hundreds of subjects under study are high. As in complex diseases in general, the severity and the clinical findings of the disease vary between different patients and also individually during a patient's lifetime. At the same time, the diagnosis of asthma is still predominantly based on a characteristic pattern of symptoms and a measurable reversible airway obstruction and/or bronchial hyperreactivity (BHR) (6). However, both the sensitivity of different lung function tests and the predictive value of any positive test have been shown to be generally low (7) and the repeatability of quantitative traits associated to asthma, such as BHR, is low (8). Inflammation in a bronchial biopsy specimen supports the diagnosis, but does not have any pathognomonic features compared to other characteristics of allergic inflammation (9). Because of a strong association between asthma and atopy, allergy screening is often included in the diagnostic procedure. The usefulness of inflammation markers in sputum is under investigation. Asthma-like symptoms especially among the first degree relatives of asthma patients are common (2,lO). Verification of the affection status of these family members in a single cross-sectional time point can be extremely difficult. On the other hand, an accurate diagnosis is considered to be crucial in monogenic diseases where gene mapping and positional cloning have identified disease causing gene defects (11). For the complex trait of asthma, it is not known whether a certain clinical subphenotype or a certain quantitative trait associated with asthma (serum IgE level or BHR) can better predict homogeneity in the molecular mechanisms of the disease (12,13).
We recruited families for genetic studies of asthma in a province of Finland, hoping to take advantage of the genetic features of the Finnish population (5,ll). In Finland, the Social Insurance Institution (SII) grants a substantial reimbursement for asthma medication to all patients who meet diagnostic criteria such as asthmatic symptoms and reversible airway obstruction measured by spirometry or peak expiratory flow and/or positive histamine or methacholine challenge test (Table 1) . This procedure assures that especially patients who need regular medication are carefully diagnosed, including basic lung function testing before medication is started. The grounds for asthma diagnosis are nationally uniform and based on the recommendation of American Thoracic Society (6). In our study other aspects of the study design also favour the uniformity of diagnoses: the probands have been recruited from a geographically small region only and represent about 8% of the asthma patients of the province. Most of the diagnoses have been made in a single clinic for pulmonary medicine which has employed only few physicians over the years. In the year 1994, the proportion of people entitled to reimbursed anti-asthmatic medication was 3.4% in Kainuu and 2.8% in the whole country (14) .
This study was designed to answer the following questions: could self-reported asthma be verified by the granted reimbursement by the SII and could self-reported allergic nasal symptoms or self-reported physician diagnosed allergic rhinitis be used alone as markers of airway allergy? To answer these questions, we reviewed the hospital files retrospectively to verify the diagnostic criteria for asthma and compared all this information with the self-reported data. In order to test the applicability of questions 'Have you ever been diagnosed with allergic rhinitis by a physician? and 'Have you ever suffered from allergic nasal symptoms?', the responses of participants were compared with our allergy blood screening results.
Materials
and Methods
STUDY POPULATION
Study families were recruited through local newspapers and radio stations in Central Eastern Finland (Kainuu Province) during November 1994. The study area consists of one small town (36 859 inhabitants) and its rural surroundings (altogether 9.5 814 inhabitants). The area belongs to a continental subarctic climatic region with cold and snowy winter and cool and short summer. The selection criteria for a proband were: self-reported asthma diagnosed by a physician, the parents and/or grandparents born in Kainuu and the nuclear family willing to participate (proband -spouse -at least one child, or probandmother -father, or proband ~ one of the parents -at least one sibling) [ Fig. l(c) ]. Additional affected family members (uncles, aunts, grandparents, cousins, further siblings) were included when available. The sample set was formed of 255 nuclear families including 54 large pedigrees with multiple affected. All participants signed an informed consent where they gave permission to use their blood samples for a scientific study. They were also asked in which hospitals they had been diagnosed and treated and to give permission for their hospital files concerning asthma and allergy to be studied. The National Board of Health confirmed the permission to access these patients' medical records. . During a brief interview of the probands, the questionnaire was clarified and the written answers were discussed with a physician. The questions concerning allergies, smoking habits and other diseases were identical for probands and family members whereas the questions concerning respiratory symptoms were more detailed for the self-reported asthma patients.
MEDICAL RECORDS
On the basis of self-reported asthma, the medical records of probands were then reviewed separately by two pulmonary physicians [ Fig. l(f) ]. Descriptive remarks of the clinical condition and lung function test results were collected in a standardized form. The reversibility of airway obstruction and BHR were evaluated. Diagnostic results were considered, e.g. improvement by at least 15% of forced expiratory volume in 1 s (FEV,) with &-agonist or decrease of FEV, in histamine or methacholine challenge by at least 1.5% (Table 1) . Patients whose lung function tests had remained non-diagnostic or were insufficiently carried out or documented at the time of diagnosis were followed through hospital records to obtain objective evidence either for or against asthma diagnosis. At the same time, other diseases were excluded as a possible cause for the patient's dyspnoea, such as respiratory insufficiency with a history of pulmonary tuberculosis.
TOTAL SERUM IGE AND SPECIFIC IGE ANTIBODIES
Probands with self-reported asthma (~~~335) represented an adult population (mean age of 45 years, range from 16 to 83 years) with a dominance of women (68%). Two pulmonary physicians reviewed and merged all available data from medical records and questionnaires filled in by the participants. Based on those data the patients were divided into six diagnostic categories (Table 2 ). In 239 (71%) of the patients, self-reported asthma was confirmed based both on medical history and diagnostic lung function tests showing either reversible airway obstruction or BHR or both (Table  3 ). The group of probable asthma (n = 54, 16%) included all patients whose medical records revealed similar and recurrent symptoms of asthma as in the group of confirmed asthma, but as regards the documentation of lung function tests, these two groups differed. In the latter group, the tests were either insufficiently done or the results were not diagnostic according to our criteria (Table 1) . Twenty of these patients had developed asthma in young adulthood (Table 3) . However, both groups represented patients who had been regularly followed up by a physician and who had used regular anti-inflammatory medication for 5 years on average. Both groups also reported a constant need for medication and a clinical response to medication shown as a relief of asthma symptoms. Ninety-six per cent of the probands in the group with confirmed asthma had medication costs reimbursed by SII, while the corresponding number for the group with probable asthma was 89%. Serum samples were stored at -70°C and analysed in one
In the group with possible asthma (n= 14), some asthma batch in the same laboratory.
The neither recurrent symptoms nor a need for medication had developed (Table 3) . None of the individuals in this group had reimbursement for medication. The group with chronic obstructive pulmonary disease (COPD, n= 12) included all patients who had smoked for over 20 yr. The main component of their disease was irreversible obstruction of the airways developed at an average age of 57 years, and seven individuals in this group had SII reimbursement for medication. Three patients had a history of lung tuberculosis causing respiratory insufficiency, two of the patients had a systemic disorder with pulmonary involvement, and one had a severe heart condition. All these patients had dyspnoea, but no clinical evidence of asthma, although two persons with a history of lung tuberculosis had developed a respiratory insufficiency with an obstructive component and thus were entitled to the reimbursement by SII. In 10 patients the medical records were insufficient or not available for classification.
On the whole, reimbursement for medication showed a sensitivity of 95% (277/293) and a specificity of 76% (32/42) among the self-reported asthma patients when compared to our combined data of self-reported asthma and information on medical records as a standard. Of all self-reported asthma patients, asthma was verified in 87% (293/335) and of those with granted reimbursement, asthma was verified in 97% (277/287) ( Table 2) .
Twenty-seven per cent of the family members who had never been diagnosed as having asthma (n=403) reported symptoms of dyspnoea and/or wheezing, 37% reported recurrent airway infections, and 24% reported prolonged cough. Fifty-three family members (13%) reported the occasional use of anti-asthmatic medication at some point in their lives.
SELF-REPORTED ALLERGIC RHINITIS
Screening for IgE-mediated allergy was done for the most common aeroallergens in Finland (20) . The allergy screening test results (PhadiatopB) were used as the objective verification to calculate sensitivity, specificity and predictive values. The test results were compared to the participants' responses to both of the questions on nasal allergic symptoms and on physician diagnosed allergic rhinitis among the asthma patients and among their family members (Table 4) . However, neither of the questions reached a high sensitivity, specificity or positive or negative predictive value. Among the self-reported asthma patients, 90% of the allergy screening positive, but also 69% of those screening negative, reported symptoms of allergic rhinitis. The corresponding figures among their family members were 71% and 41%, respectively. Physician diagnosed allergic rhinitis showed a better specificity than self-reported allergic symptoms in both of the groups. Seventeen percent of the asthma patients and 18% of the family members did not answer the question of physician diagnosed allergic rhinitis.
Clinically, the allergy screening positive and negative participants differed in age (mean 36 vs 50 years, RO.0001) and in smoking habits (current smokers 25% vs 14%, P<O.O05), whereas gender did not have a significant effect (males 45% vs 41%, respectively).
As expected, allergy screening was more frequently positive among the asthma patients (41%) than among their family members (21%, WO.0001). Serum total IgE levels were significantly higher in the screening positive group (mean 390 kU 1-i) compared to the allergy screening negative group (mean 66 kU 1~ '; P<O.OOOl). Among allergy screening positive individuals, 51% had specific IgE antibodies for timothy, 51% for cat, 45% for dog, 43% for house dust mite, 36% for birch, 18% for mugwort, and 10% for the mould Cludospouium herbavum. The spectrum of allergy antibodies among the asthma patients did not differ from that found among the family members, but the screening positive asthma patients had more frequently two or more specific antibodies elevated (72%) compared to their non-asthmatic family members (49%, P<O.OOl).
Discussion
Our study showed that asthma is a well-known disorder among Finns, and that the nationwide criteria of chronic diseases employed by the SII can offer valid information on diagnostic findings. Granted reimbursement for medication showed a sensitivity of 95% and a specificity of 76% among the probands when compared to our combined data used as a reference. Of those with granted reimbursement for medication, 97% were verified as having asthma. Of all the self-reported asthma patients asthma could be verified in 87%. These figures show that the reimbursement procedure is a good predictor for asthma, but not all true asthmatics had reimbursement.
Differences in the documentation of lung function tests can be explained by the fact that for 19 patients in the group with probable asthma the diagnosis of asthma was made long ago (>14 years) compared to the patients in other diagnostic groups. Thus, we may have failed in some cases to trace the actual test results. For 20 patients the diagnosis was made already in childhood and relied on the clinical picture alone. These two groups of patients have been included in our further studies on the genetics of asthma (22) .
The main confounding groups of patients were long-term smokers (4%) and patients with mild asthma-like symptoms that were not diagnosed as chronic asthma at the time of the study (4%). In both conditions, the clinical picture of the disease resembles that of asthma and medication is often indicated. It is possible that the same genetic factors predisposing to asthma also have a role in the development of COPD, and that the responders with mild respiratory distress will later develop chronic asthma. However, these patients, like the responders with some other pulmonary or heart disease (2%) were excluded to avoid heterogeneity in the aetiology of airway obstruction. For 3% of patients we were not able to trace any medical records on asthma and they were also excluded.
The results concerning allergic rhinitis were more controversial. Ninety per cent of the allergy screening test positive asthma patients and 71% of the allergy screening test positive family members had self-reported allergic rhinitis, but many individuals with a negative allergy screening test (69% and 41%, respectively) also reported symptoms. Among both the asthma patients and their family members, the question of physician-diagnosed allergic rhinitis showed a higher specificity, but a lower sensitivity than selfreported allergic nasal symptoms (Table 4) . Chronic rhinitis, either allergic or vaso-motoric in origin, is common especially among asthmatics (23) . The difference diagnosis between these subtypes depends on whether the symptoms are associated with allergen exposure and a specific IgE response. However, IgE mediated reactivity is known to diminish with age (24) . The discordance between allergic symptoms and screening results was greater than previously published among Finnish adolescents (21) . This might be explained by the difference in the age distribution and by the question designed to assess either 'current allergies' or 'allergies ever' as in our study (21) . Even though atopy is indisputably increasing in Finland as in other industrialized countries (25, 26) , the high number of allergy screening positive individuals among the young study subjects may partly be due to an age-dependent, strong IgE response. In addition to age, current smoking was shown to elevate IgE levels which can also act as a confounding factor in genetic (30, 31) . The occurrence of airway allergies or the spectrum of the allergies did not differ from those found in recent epidemiological studies in Finland (27) and Sweden (32) . Based on all information, in our forthcoming genetic studies airway allergy is defined as either a positive allergy screening, or an elevated serum total IgE level (> 100 kU l-') with accompanying allergic symptoms of the airways.
Reviewing the medical records was time-consuming but could still be regarded as cost-effective in this population where the diagnostic criteria of asthma are uniform because of the SII reimbursement procedure. Except for the blood tests, there was no need for extra tests such as spirometrics or bronchial challenge tests that would have been inconvenient for the participants and expensive to carry out. Lung function testing had already been done for the majority of the self-reported asthma patients: a spirometry had been done in 99% of the patients and a PEF monitoring in 88% of the group with confirmed asthma (Table 3) . Also, if the lung function tests had been done now the findings would have probably been different from those done at the time of diagnosis for each patient, or less clear because of the given treatment with anti-inflammatory agents, both factors being likely to introduce further heterogeneity.
Several family studies before ours have shown an increased incidence of asthma among first degree family members of asthma patients in comparison to general population (l,lO). In our study, 13% of the family members reported the use of anti-asthmatic medication at some point of their lives even though a specific diagnosis had never been made. By choosing not to do physical examinations among the family members, we have probably lost some affected family member pairs, but avoided false-positive affected pairs. Furthermore, not even the most careful clinical examination can predict the risk of morbidity among the unaffected. Misclassification of asthma patients as controls tends to be conservative for statistical calculations since group differences become diminished rather than exaggerated. Thus, any positive findings of significant differences are likely to be real. For genetic linkage disequilibrium studies in which the allele or haplotype frequencies among the affected are compared to the controls, unaffected spouses of the asthma patients represent optimal familyand population-based controls. The study of an isolated population may offer specific advantages for genetic studies because of reduced genetic heterogeneity (5, 11, 29) . In addition, medical diagnostics tend to be more uniform in a regionally restricted population.
We have taken advantage of these features and the standardized diagnostic procedures for asthma in Finland. With objective verification for diagnoses of asthma and allergic rhinitis, the study group should be especially well suited for genetic studies (22) .
We conclude that self-reported diseases, such as asthma, can be used as a sampling method and by combining this with valid retrospective data on diagnostic findings it can be used as an efficient approach for large epidemiological or genetic studies. These principles might also be applicable in other populations with similar organization of asthma care. The general knowledge of allergic symptoms is not specific and thus self-reported allergies also need to be verified by objective measurements.
